Stifel Maintains Buy on EyePoint, Lowers Price Target to $5
EyePoint Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary
EyePoint: Q3 Earnings Snapshot
EyePoint Reports Third Quarter 2026 Financial Results and Provides Recent Corporate Developments
EyePoint, Inc. (EYPT) Q3 2026 Earnings Call Transcript
EyePoint Pharmaceuticals Q3 2026 Earnings Call Transcript
EyePoint Pharmaceuticals Q3 EPS $(1.07) Misses $(0.91) Estimate, Sales $756.000K Beat $223.077K Estimate
EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meetings
EyePoint to Report Third Quarter 2026 Financial Results on November 12, 2026
EyePoint: DME Upside Remains, But Financing Could Consume Most Of It (Rating Downgrade)
EyePoint (EYPT) Expected to Beat Earnings Estimates: Should You Buy?
EyePoint (EYPT) Stock Sees Fair Value Cut After Duravyu Trial Setbacks
Laidlaw & Co. Downgrades EyePoint to Hold
RBC Capital Maintains Sector Perform on EyePoint, Lowers Price Target to $1
Guggenheim Downgrades EyePoint to Neutral
EYPT Stock Layoffs: What to Know About the Latest EyePoint Job Cuts
Most Active Stocks: SAFX, WFF and EYPT in Heavy-Volume Session
EyePoint Drug Trial Flop Crashes Stock. Can a Strategy Shift Save It?
EyePoint: Stock Takes Shellacking On Second Pivotal Eye Disease Study Miss
EyePoint crashes as pivotal wet AMD trial fails, prompting 53% workforce cut
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.